Clinical trial · NCT06760819 · RECRUITING · PHASE2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Sponsor: Bayer
Summary
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn how well BAY2927088 (sevabertinib) works in people with different types of solid tumors with HER2 mutations. These include tumors in the colon or rectum, the uterus and the cervix (lower part of the uterus), the breast, the bladder, and the biliary tract (includes gall bladder and bile ducts) as well as other types of solid tumors with the exception of people with advanced non-small cell lung cancer (NSCLC). Solid tumors may have specific changes or mutations to a gene called human epidermal growth receptor-2 (HER2). This leads to the formation of an abnormal form of HER2 protein in the cancer cells, resulting in increased cell growth. The study treatment, BAY2927088, is expected to block the abnormal HER2 protein which may stop the spread of cancer. The trial will include about 111 participants who are at least 18 years old. All the participants will take 20 mg of BAY2927088 as tablets by mouth. The participants will take treatments in 3-week periods called cycles. These 3-week cycles will be repeated throughout the trial. The participants can take BAY2927088 until their cancer gets worse, until they have medical problems, or until they leave the trial. During the trial, the doctors will take imaging scans of different parts of the body to study the spread of cancer and will check heart health using echocardiogram or cardiac magnetic resonance imaging (MRI) and electrocardiogram (ECG). The doctors will also take blood and urine samples and do physical examinations to check the participants' health. They will ask questions about how the participants are feeling and if they have any medical problems.
Interventions
- BAY2927088 · DRUG
tablet, oral
Published eligibility criteria
Verbatim from the registry. Only the site can decide how these apply to a specific patient.
Inclusion Criteria: * Documented histologically or cytologically confirmed locally advanced, unresectable or metastatic solid tumor cancer (colorectal carcinoma; biliary tract cancer; bladder and urothelial tract cancer; cervical cancer; endometrial cancer; breast cancer; other solid tumor cancer, excluding NSCLC) * Participant must be ≥18 years of age or over the legal age of consent * Patients who have received prior standard therapy appropriate for their tumor type and stage of disease, or who have no satisfactory alternative treatments * Documented activating HER2 mutation * At least one measurable lesion that would qualify as a target lesion by RECIST 1.1 criteria Exclusion Criteria: * Primary diagnosis of non-small cell lung cancer (NSCLC) * Prior treatment with a HER2 tyrosine kinase inhibitor (TKI) * Active brain metastases * Uncontrolled, severe, intercurrent illness
Sites (54)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham, Alabama · RECRUITING
- City of Hope - Duarte Cancer Center, Duarte, California · RECRUITING
- Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus, Fort Myers, Florida · RECRUITING
- Dana-Farber Cancer Institute - Oncology Department, Boston, Massachusetts · RECRUITING
- Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit, Detroit, Michigan · WITHDRAWN
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills, Michigan · RECRUITING
- Cleveland Clinic - Oncology Department, Cleveland, Ohio · RECRUITING
- SCRI Oncology Partners, Nashville, Tennessee · RECRUITING
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston, Texas · RECRUITING
- Gynecology Oncology clinic at UW Medical Center - Montlake, Seattle, Washington · WITHDRAWN
- UW Health Carbone Cancer Center, Madison, Wisconsin · RECRUITING
- NSW Health - Blacktown Hospital, Blacktown, New South Wales, Australia · RECRUITING
- Macquarie University Hospital - Oncology Department, Sydney, New South Wales, Australia · RECRUITING
- ICON Cancer Centre - Southport, Southport, Queensland, Australia · RECRUITING
- Queen Elizabeth II Health Sciences Centre | Oncology, Halifax, Nova Scotia, Canada · RECRUITING
- Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology, Toronto, Ontario, Canada · RECRUITING
- McGill University Health Centre - Glen Site - Women Health's Research Unit, Montreal, Quebec, Canada · RECRUITING
- Peking University First Hospital - Oncology Department, Beijing, Beijing Municipality, China · RECRUITING
- Beijing Cancer Hospital - Oncology Department, Beijing, Beijing Municipality, China · RECRUITING
- Hunan Cancer Hospital - Oncology Department, Changsha, Hunan, China · RECRUITING
- Fudan University Shanghai Cancer Center - Oncology Department, Shanghai, Shanghai Municipality, China · RECRUITING
- Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China · RECRUITING
- Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department, Hangzhou, Zhejiang, China · RECRUITING
- Rigshospitalet Copenhagen University Hospital | Oncology Department, Copenhagen, Capital Region, Denmark · RECRUITING
- Aarhus University Hospital | Oncology Department - Clinical Research Unit, Aarhus N, Central Jutland, Denmark · RECRUITING
- Odense University Hospital | Svendborg Sygehus - Oncology Department, Odense, Region Syddanmark, Denmark · RECRUITING
- Centre Hospitalier Lyon Sud - Service oncologie medicale, Pierre-Bénite, Auvergne-Rhône-Alpes, France · RECRUITING
- CHU Brest - Hopital La Cavale Blanche - service oncologie medicale, Brest, Brittany Region, France · RECRUITING
- Centre Oscar Lambret - Service Oncologie, Lille, Hauts-de-France, France · RECRUITING
- Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale, Bordeaux, New Aquitaine, France · RECRUITING
- ICM - Institut du Cancer de Montpellier - Val d'Aurelle - CIPP, Montpellier, Occitanie, France · RECRUITING
- Institut Gustave Roussy - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP), Villejuif, Île-de-France Region, France · RECRUITING
- Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1, Milan, Italy · RECRUITING
- Istituto Europeo di Oncologia s.r.l - Ginecologia Oncologica Medica, Milan, Italy · RECRUITING
- Azienda USL IRCCS di Reggio Emilia_Arcispedale Santa Maria Nuova - S.C. Oncologia Provinciale, Reggio Emilia, Italy · RECRUITING
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica, Roma, Italy · RECRUITING
- Aichi Cancer Center Hospital, Nagoya, Aichi-ken, Japan · RECRUITING
- National Cancer Center Hospital East (NCCHE) - Kashiwa Campus, Kashiwa, Chiba, Japan · RECRUITING
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan · RECRUITING
- Kindai University Hospital, Sakai, Osaka, Japan · RECRUITING
- National Cancer Center Hospital, Chuo-ku, Tokyo, Japan · RECRUITING
- The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan · RECRUITING
- Seoul National University Hospital, Seoul, South Korea · RECRUITING
- Severance Hospital, Yonsei University Health System - Oncology Department, Seoul, South Korea · RECRUITING
- Asan Medical Center | Oncology, Seoul, South Korea · RECRUITING
- Samsung Medical Center - Oncology Department, Seoul, South Korea · RECRUITING
- Institut Catala D'oncologia | Hospitalet | Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain · RECRUITING
- Clinica Universidad De Navarra | Madrid | Oncologia, Madrid, Navarre, Spain · RECRUITING
- Instituto Oncologico Dr. Rosell S.L. | Oncologia, Barcelona, Spain · RECRUITING
- Hospital Universitari Vall D Hebron | Oncologia Medica, Barcelona, Spain · RECRUITING
- Hospital Universitario Fundacion Jimenez Diaz | Oncologia Medica, Madrid, Spain · RECRUITING
- Inselspital Bern - Universitätsklinik für Medizinische Onkologie, Bern, Switzerland · RECRUITING
- Hopitaux Universitaires de Geneve - Oncology Department, Geneva, Switzerland · RECRUITING
- UniversitätsSpital Zürich (USZ) - Klinik für Medizinische Onkologie und Hämatologie, Zurich, Switzerland · RECRUITING
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-07-07.